Loading
Heart Failure / Heart Failure With Reduced Ejection Fraction / Omecamtiv Mecarbil (OM) · Phase 3 Trial
ClinicalTrials.gov · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 RCT registration for omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure and severely reduced ejection fraction. No results have been posted in this registry record; the study is actively recruiting with an estimated 3-year follow-up for composite hard clinical outcomes including death, hospitalization, and transplantation.
Phase 3, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Heart Failure, Heart Failure With Reduced Ejection Fraction; age from 18 Years; to 85 Years. Intervention: Omecamtiv Mecarbil. Compared with: Placebo — Placebo Comparator. n = 1,800. 201 sites across 10 countries.
This is a Phase 3 RCT registration for omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure and severely reduced ejection fraction. No results have been posted in this registry record; the study is actively recruiting with an estimated 3-year follow-up for composite hard clinical outcomes including death, hospitalization, and transplantation.
No outcome data, effect sizes, or safety information are available.
The source did not state who this applies to in practice.
This is a Phase 3 trial registration with no results posted; the study is actively recruiting and has not yet reported outcomes, making it an early-stage record describing a planned intervention.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06736574). This is a study registration, not published results. Lead sponsor: Cytokinetics. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 1800 participants (ESTIMATED). Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction. Interventions: DRUG: Omecamtiv Mecarbil (OM); DRUG: Placebo. Primary outcome measures: Time to the first of event of CV death, HF event, LVAD implantation/cardiac transplantation, or stroke , From randomization to the first event of CV death or HF event, whichever occurs first, assessed until the last patient exits the study, estimated to last about 3 years. Brief summary: The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.